Articles about Puma Biotechnology
Puma Biotechnology Inc (PBYI) Stock Price & Performance 2023
Accord entre Pierre Fabre et Puma Biotechnology
Puma Biotechnology
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Dennis Sanders - Senior Clinical Specialist - Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Puma Biotechnology
Puma Biotech secures $100 million loan to market its breast cancer drug - L.A. Business First
Henry Kuo - Head of Information Technology - Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology Inc
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Puma Biotech plunges on drug side effects
Puma Biotechnology Surging
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Puma Biotechnology Inc Share Price USD0.0001
Puma Biotechnology
Puma Biotech Rebranding — Alex Maurer Designs
